Clofoctol
Chemical compound
- J01XX03 (WHO)
- 2-[(2,4-dichlorophenyl)methyl]-
4-(2,4,4-trimethylpentan-2-yl)phenol
- 37693-01-9 Y
- 2799
- 2697 Y
- 704083NI0R
- D07244 Y
- ChEMBL1476605
- DTXSID5045889
- Interactive image
- Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C
InChI
- InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3 Y
- Key:HQVZOORKDNCGCK-UHFFFAOYSA-N Y
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.[citation needed]
It is only functional against Gram-positive bacteria.[2]
It penetrates into human lung tissue.[3]
A French company, Apteeus had been developing clofoctol as a potential therapy against SARS-CoV-2 in 2020-2021, but eventually the repurposing of the drug was abandoned, due to a lack of volunteers.[4][5]
References
- ^ a b c d e "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.
- ^ Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.
- ^ Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.
- ^ "Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" (in French). AEF info. October 13, 2020. Retrieved 2020-10-13.
- ^ "La piste clofoctol. Interview du Pr Xavier Nassif". Jim.fr. 13 September 2021.
- v
- t
- e
- cresol: Clofoctol
- pyran/fatty acid: Isoleucine-tRNA ligase inhibitors (Mupirocin)
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e